| Title |
The use of platensimycin and platencin to fight antibiotic resistance
|
|---|---|
| Published in |
Infection and Drug Resistance, September 2013
|
| DOI | 10.2147/idr.s25076 |
| Pubmed ID | |
| Authors |
Adil M Allahverdiyev, Melahat Bagirova, Emrah Sefik Abamor, Sezen Canim Ates, Rabia Cakir Koc, Meral Miraloglu, Serhat Elcicek, Serkan Yaman, Gokce Unal |
| Abstract |
Infectious diseases are known as one of the most life-threatening disabilities worldwide. Approximately 13 million deaths related to infectious diseases are reported each year. The only way to combat infectious diseases is by chemotherapy using antimicrobial agents and antibiotics. However, due to uncontrolled and unnecessary use of antibiotics in particular, surviving bacteria have evolved resistance against several antibiotics. Emergence of multidrug resistance in bacteria over the past several decades has resulted in one of the most important clinical health problems in modern medicine. For instance, approximately 440,000 new cases of multidrug-resistant tuberculosis are reported every year leading to the deaths of 150,000 people worldwide. Management of multidrug resistance requires understanding its molecular basis and the evolution and dissemination of resistance; development of new antibiotic compounds in place of traditional antibiotics; and innovative strategies for extending the life of antibiotic molecules. Researchers have begun to develop new antimicrobials for overcoming this important problem. Recently, platensimycin - isolated from extracts of Streptomyces platensis - and its analog platencin have been defined as promising agents for fighting multidrug resistance. In vitro and in vivo studies have shown that these new antimicrobials have great potential to inhibit methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae by targeting type II fatty acid synthesis in bacteria. Showing strong efficacy without any observed in vivo toxicity increases the significance of these antimicrobial agents for their use in humans. However, at the present time, clinical trials are insufficient and require more research. The strong antibacterial efficacies of platensimycin and platencin may be established in clinical trials and their use in humans for coping with multidrug resistance may be allowed in the foreseeable future. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 1% |
| Chile | 1 | 1% |
| Austria | 1 | 1% |
| Argentina | 1 | 1% |
| China | 1 | 1% |
| Poland | 1 | 1% |
| Unknown | 71 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 14% |
| Student > Bachelor | 11 | 14% |
| Student > Doctoral Student | 10 | 13% |
| Student > Master | 10 | 13% |
| Student > Ph. D. Student | 8 | 10% |
| Other | 15 | 19% |
| Unknown | 12 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 27 | 35% |
| Medicine and Dentistry | 9 | 12% |
| Chemistry | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 7 | 9% |
| Unknown | 18 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2013.
All research outputs
#14,761,535
of 22,723,682 outputs
Outputs from Infection and Drug Resistance
#595
of 1,617 outputs
Outputs of similar age
#119,397
of 200,188 outputs
Outputs of similar age from Infection and Drug Resistance
#5
of 7 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,617 research outputs from this source. They receive a mean Attention Score of 3.9. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,188 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.